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Major Role for Interleukin 1 but Not for Tumor 
Necrosis Factor in Early Cartilage Damage in 
Immune Complex Arthritis in Mice
PETER L.E.M. VAN LENT, FONS A.J. VAN DE LOO, ASTRID E.M. HOLTHUYSEN, 
LIDUINE A.M. VAN DEN BERSSELAAR, HARRY VERMEER, and WIM B. VAN DEN BERG
ABSTRACT. Objective. To determine the regulating role of interleukin*-1 a and ft (IL-la,U) and tumor necrosis
factor a (TNF-a) on inhibition of proteoglycan synthesis and proteoglycan degradation in early im­
mune complex arthritis (ICA) in the mouse.
Methods. In the early phases of arthritis, IL-1 and TNF were measured using cytokine specific bio­
assays, the NOB. I EL-4 and L929 assay, respectively. The impact of IL-1 in proteoglycan synthe­
sis was studied by neutralizing the formed IL-1 during early arthritis either by giving anti-IL-1 specific 
antibodies intravenously or IL-1 receptor antagonist (IL-lra) intraperitoneally by osmotic pumps. 
TNF-a was neutralized by giving monoclonal antibodies directed against murine TNF-a. Synthesis 
of proteoglycans was measured ex vivo by uptake of 35S-sulfate by patellae derived from inflamed 
and control, noninflamed knee joints. In vivo formation of-^S-sulfate labeled proteoglycans was 
studied by autoradiography. Degradation of proteoglycans was measured by labeling patellae in vivo 
with 3SS-sulfate before arthritis induction.
Results. High levels of IL-1 are formed during the first phase of immune complex arthritis (ICA). 
Neutralization of either IL-1 a or ft with specific polyclonal antibodies resulted only in partial block­
ing, whereas a combination fully blocked inhibition of proteoglycan synthesis. Full blocking was 
also found after systemic treatment with high amounts of IL-1 receptor antagonist (1.2 mg/day dur­
ing 3 days). Influx of cells was also significantly reduced both in the anti-IL-1 as well as in the 
IL-lra treated groups. Whether infiltrating cells are involved in inhibition of proteoglycan synthesis 
was further investigated in neutropenic mice. Significantly higher levels of IL-1 were found in ar­
thritic joints of neutropenic compared with control mice. Suppression of proteoglycan synthesis was 
similar in arthritic knee joints of normal and neutropenic mice. However, only minor proteoglycan 
degradation was found in the latter. TNF-a was undetectable in the bioassay in early ICA and neu­
tralization of TNF-a did not change either swelling, cell influx, proteoglycan synthesis or proteoglycan 
degradation.
Conclusion. Local production of IL-1 in ICA in knee joints seems directly responsible for inhibi­
tion of proteoglycan synthesis, A direct role of IL-1 in proteoglycan loss is unlikely, but indirectly 
IL-1 may be involved in proteoglycan breakdown by attracting inflammatory leukocytes and ac­
tivating synovial cells. TNF-a seemed to have no effect on either celt influx, proteoglycan synthesis 
or proteoglycan degradation in this model. (J Rheumatol 7995/22:2250-8)
Key Indexing Terms:
EXPERIMENTAL ARTHRITIS IMMUNE COMPLEXES IL-1
IL-1 RECEPTOR ANTAGONIST TUMOR NECROSIS FACTOR
CARTILAGE DAMAGE
One of the main features of joint inflammation is the altera­
tion of homeostasis of chondrocyte function, which may lead 
to cartilage destruction. In normal cartilage a balance exists 
between anabolism and catabolism of proteoglycans, one of
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the main constituents of cartilage determining its compres 
sive resilience. In experimental arthritides the disturbance 
of this balance is shown by severe inhibition of proteogly 
can synthesis and enhanced degradation of proteoglycan1'3 
Tumor necrosis factor a (TNF-a) and interleukin 1 (IL-1 
are believed to play a crucial role in these effects. Enhancec
cytokine levels are found during the early phases of expert 
mental arthritides4-8. Moreover, it is known from in vitrc 
experiments that both IL-1 and TNF~a added to living 
explants of cartilage induce breakdown and marked inhibi 
tion of proteoglycan synthesis, with IL-l being more 
potent9-11. Moreover, relatively high doses of IL-1 an 
needed to cause breakdown, whereas low doses inhibit pro
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teoglycan synthesis9“11. In vivo IL-1 was shown to cause 
joint inflammation and marked proteoglycan depletion after 
direct injection in the knee joints of rabbits1, rats12, and 
mice3. Experiments blocking the influx of neutrophils 
revealed that cell influx had no direct effect on cartilage13. 
In experimental arthritis the role of IL-1 and TNF in car­
tilage destruction is less clear. Although IL-l could be de­
tected in the synovial tissue, the concentrations are proba­
bly too low to cause proteoglycan breakdown directly, 
whereas it may be sufficient to initiate inhibition of proteo­
glycan synthesis. In antigen induced arthritis it was found 
that blocking of IL-1 with antibodies7 or IL-1 receptor anta­
gonist (IL-lra) 14 prevented inhibition of proteoglycan syn­
thesis, independent of joint inflammation. However, break­
down of proteoglycan was unaffected, suggesting the strong 
influence of other mediators. In contrast, IL-l blocking in 
collagen arthritis was effective on both synthesis and break­
down but the latter result is probably related to the marked 
suppression of joint inflammation in this model15. We at­
tempted to further elucidate the role of IL-1 and TNF in the 
breakdown and synthesis of proteoglycan, and the influence 
of infiltrating leukocytes. We used the recently developed 
model of cationic immune complex arthritis (ICA) in mice8, 
a model characterized by marked IL-1 production, 
pronounced IL-1 dependent cell influx, and early cartilage 
damage. Moreover, proteoglycan degradation is clearly de­
pendent on infiltrating leukocytes, although no role could 
be attributed to PMN elastase16. We studied the cartilage 
destruction and cytokine profiles in both normal and neu­
tropenic mice and analyzed the effect of neutralization of 
IL-la, 6 and TNF-a using subtype specific antibodies and 
IL-lra.
MATERIALS AND METHODS
Animals. Male C37 bl/6 micc were’obtained from our breeding facilities 
(Overasselt, The Netherlands). They were fed a standard diet and tapwater 
ad libitum. Their age was between 8 and 12 weeks at the time of study,
Chemicals. Poly-L-lysine (PLL), lysozyme, and l-ethyl-3(3-dimethyl- 
aminopropyl) earbodiimide (EDC) were obtained from Sigma Chemical 
Company, St. Louis, MO, USA. N,N-dimetbyl-l,3 propanediamine was 
obtained from BDH Chemicals Ltd., Poole, England.
Lysozyme coupling to PLL. Lysozyme was coupled to PLL according to 
the method of Danon17 using EDC as an activator and PLL as a nucleophile 
as described ^  Free carboxyl groups of the protein are then coupled to 
aminogroups of PLL. The molecular weight was raised whereas the iso­
electric point remained high as was determined in a 5% polyacrylamide 
slab gel with 0.8% ampholines (pH gradient from 3.5 to 9,5). The molecu­
lar weight appeared to be 74 kDa as determined by sodium dodecyl sulfate 
polyachrylamide gel electrophoresis.
Induction of ICA. PLL-iysozyme (3 /¿g) was injectcd into the right knee 
joint of mice previously given specific antisera (0.2 ml) directed against 
lysozyme intravenously (iv). The antisera, raised in rabbits, were decom- 
plementized by heating at 56 °C for 30 min. The left knee joint was inject­
ed with saline and served as a control.
Polymorphonuclear (PMN) depletion. Micc were depleted of PMN by either 
total body irradiation or cyclophosphamide treatment. A single dose of 7.5 
Gy was applied at a dose rale of 2 Gy/min, with a 13 MV electron beam, 
from a linear accelerator (CGR Saturne, Buc, France). Treatment was started
4 days before injection of the antiserum. Mice were anesthesiz<xl by in- 
traperitoneal (ip) injection of sodium pentobarbital, 0.03 mg/g body weight 
(Narcovet®, Apharma B.V., Arnhem, The Netherlands) and placed between
2 perspex plates, the upper one 1 cm thick. Cyclophosphamide (Endoxan- 
Asta®, Asta Medica AG, Frankfurt am Main, Germany) was given ip at 
Day 4 (150 mg/kg) and Day 1 (100 mg/kg body weight) before induction 
of arthritis. To prevent infection in both irradiated and cyclophosphamide 
treated groups, mice were kept under aseptic conditions in a semisterile 
room and received acidified drinking water and sterilized food. The irradi­
ated mice were given daily supplements of 1 ml of glucose solution ip until 
injection of the antibodies. At this time, most mice had lower skin temper­
ature and bodyweight loss up to 10%.
Antiserum treatment of mice. Anti-IL-1 antibodies. Mice were given 400 
pd of a mixture: 200 /¿l of anti-IL-1 a and ii antiserum (I to 1 ratio) and 
200 fii of antilysozyme, 16 h before arthritis induction as described8. Cul­
turing arthritic patellae of anti-IL-1 treated mice revealed that IL-1 could 
not be detected in the NOB assay (data not shown).
IL-lra. IL-lra (100 mg/ml) kindly provided by Synergen, Boulder, CO, 
USA (Dr. Thompson), was brought into micro-osmotic minipumps (Alzet 
model 1007D-; Alza Corporation, Palo Alto, CA, USA). These pumps 
release 0.5 fillh during 7 days in a standard manner. The pumps were im­
planted 2 days before starting the experiment to minimalize the effect of 
stress. As controls empty pumps were implanted.
Anti-TNF antibodies. Neutralizing monoclonal antibodies (Mab) directed 
against TNF-a were injected iv. The 50,000 units of Mab V IQ 19 given 
were sufficient to fully block biologic activity of 4500 ng of TNF in the 
L929 bioassay.
Cytokine production by synovial tissue. Synovial tissue was isolated in a 
standard manner by dissection of patellar tendon and patellar plate. The 
tissue specimen contained the patella, tendons and synovium8. Six synovi­
al specimens from knee joints were washed in 2 ml culture medium (RPMI 
1640 medium; Dutch modification) for 1 h at room temperature. Washouts 
(undiluted or diluted 10,20,40 and 80-fold) were tested for IL-1 and TNF 
activity by sensitive bioassays. Also higher dilutions were tested 
(160-320-fold) but in most washouts, no IL-1 /TNF signal was detected.
m
Bioassay for IL-1. IL-1 activity was measured in the one stage bioassay 
for IL-1 as described by Gearing, et aP°. The assay is performed as a 
coculture of the IL-1 specific subclone of the murine thymoma cell EL-4, 
designated NOB-1 cell, producing IL-2 and IL-4, with the lymphokine 
responder CTLL line. In brief EL-4 cells were washed twice and resuspended 
at 5 x 106 cells per ml RPMI containing 5% fetal calf scrum (FCS). The 
cells were distributed into 96 well microtiter plates at 2 x 105 cells/well 
in 100 fx 1 volumes. CTLL cells (4 x 104) were added in 50 ¡A RPMI fol­
lowed by appropriate dilutions of test sample to a final volume of 200 p\, 
After 20 h, 0.5 (id  3H-thymidine (Dupont, NEN products, Boston, MA, 
USA; specific activity 20 Ci/mmol) was added to each well, and the con­
tents harvested 3 h later, and the incorporated activity determined. The EL-4
6.1 line from which NOB-l was derived does not incorporate thymidine 
since it is deficient in thymidine kinase and therefore only CTLL prolifera­
tion is measured by 3H-thymidine incorporation. Maximal 3H-thymidine 
incorporation in the bioassay in the presence of IL -1 was between 10-12000 
cpm. CTLL alone served as control and incorporated only 100-1000 cpm, 
indicating that washouts contained only low IL-2 or IL-4 concentrations.
Bioassay for TNF-a. TNF-« activity was measured as described21. Briefly,
1 X 105 L929 cells were brought into a flat bottom 96 well microtiter plate. 
A standard curve was made by adding serial 2~fold dilutions of recombinant 
mouse TNF-a (range 0.6 to 0.0002 ng/ml). Arthritic patella washouts (di­
lution 0-3) were tested. After incubation of 20 h at 37°C and 5% C02, 
TNF-a mediated cytopathic effects on L929 cells were evaluated. The above 
dilution was gently discarded and the remaining cells fixed by adding 
methanol (96%) during 1 min. After drying of the cells, crystal violet (Sigma 
Chemical Co., St. Louis, MO) was added, and after 5 min, the excess of 
crystal viqjet washed away. The plate was then dried, 100 ¡d of acidic acid
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added, and, after shaking of the plate, the extinction determined on an ELISA 
reader at 540 nm.
Measurement of chondrocyte proteoglycan synthesis. Quantitative. Mice 
were sacrificed by ether anesthesia. The patellae from arthritic joints and 
their contralateral nonarthritic knee joints either treated with anticytokine 
antibodies, or controls were dissected leaving the cartilage intact22. After 
incubation for 3 h at 37°C in RPMI with 20 ¡xCi Na2S04/mI, tissue speci­
mens were washed, fixed in 4% buffered formalin for 20 h and decalcified 
in 5% formic acid for 4 h. The patella could thus be punched out and the 
surrounding connective tissue removed. Punched patellae, consisting of car­
tilage and bone were digested in solulyte (Lumac LSC bv, Olen, Belgium) 
for 3 h at 60°C and subsequently dissolved in Lipofluor (Lumac LSC bv, 
Groningen, The Netherlands) for liquid scintillation counting. The wash­
ing, fixation, and décalcification procedures removed all free 35S~sulfate 
from the tissue. The amount of 35S-sulfate retained is a measure of 35S pro­
teoglycans. More than 90% of the incorporated radioactivity was confined 
to the patellar cartilage layer. Comparison of radioactivity in the patella 
and that in quantitatively isolated glycoaminoglycans (GAG) [more than 
95% of the incorporated label was liberated by overnight papain digestion 
(I mg/ml)] revealed that for 35S-sulfate incorporation studies the whole 
patella can be used as a reliable measure for sulfated GAG synthesis23.
Qualitative. Autoradiography. Whole knee joint sections of joint specimens 
(6 (xM) were prepared 2 days after arthritis induction in immune mice. Three 
hours prior to sacrifice, 75 ¡jlCI 35S-sulfate was injected ip. Knee joint sec­
tions were coated on gelatine coated slides. These were dipped in K5 emulsion 
(Ilford Basildon, Essex, England) and exposed for 1-4 weeks. After this 
period the slides were developed and stained with hematoxylin and eosin24.
Measurement of proteoglycan degradation. Patellae were prelabelled by ip 
injection of radiosulfate (50 ¿¿Ci/mouse), 4 h before induction. More than 
90% of the incorporated radioactivity was confined to the patella cartilage 
layer if compared to whole patellae. At various days after arthritis induc­
tion, patellae were isolated, fixed in 2% formaldehyde and decalcified in 
4% formic acid. The patella was punched out and the labelled proteogly­
can content was determined. Cartilage degradation was defined as enhanced 
loss of 35S from the inflamed patella compared to the normal loss in the 
contralateral, noninflamed patella.
RESULTS
Production ofIL-l and TNF in ICA. Biologically active IL-1 
'and TNF production during early arthritis was measured with 
bioassays using washouts of standardized patella specimens. 
Detectable IL-1 levels were found as early as 3 h after 
arthritis induction (data not shown). Markedly enhanced 
levels were found at 6 h, whereas at 24 h no IL-1 was de­
tected (Figure 1). Production at 6 h varied between 10-30 
ptg/specimen. Biologically active TNF-a was measured us­
ing the L929 bioassay, which has a sensitivity of 1-2 pg/ml. 
TNF-ce could»not be detected in inflamed joints, 1 ,3 ,6, or 
24 h after onset of arthritis (data not shown), indicating that 
the TNF-a production is below 0.3 pg/patella. No IL-1 nor 
TNF-ce was detected in washouts of contralateral noninflamed 
joints.
Suppression of proteoglycan synthesis in ICA. ICA was 
characterized by early joint swelling and suppression of pro­
teoglycan synthesis. Joint swelling, which was correlated to 
cell influx, reached maximal values already at Day 2 (Figure 
2). Swelling varied from 1.5-1.8 at this time. At Day 7, no 
significant swelling remained. Marked suppression of pro­
teoglycan synthesis was already seen at Day 1 (Higure 2).
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Fig. L IL-1 production by patellae 6 , 24 and 48 h after induction of ICA 
in knee joints of mice. High biologically active IL-1 levels were detected 
at 6 h versus no IL-1 activity at 24 h after ICA induction, Washout dilutions 
of 10, 20, 40 and 80-fold were tested; the most sensitive to calculate IL-1 
levels was 10 or 20 (variation between experiments 17%). At 6 h 10-30 
pg and at 24 h 1-3 pg IL-1/specimen was found, No IL-1 was detected 
in washouts of contralateral noninflamed joints. In cach experiment at least 
5 mice were tested; 5 experiments were done. The above shows a 
representative experiment. Dilutions were tested twice in the bioassay and 
are expressed as mean ± SD.
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Fig, 2. Swelling and suppression of proteoglycan synthesis measured at Days 
1,2,3,4,7, and 10 after ICA induction. Swelling was determined by uptake 
of " mTc. The arthritic knee joint is compared to the nonarthritic 
contralateral knee joint, A ratio >1.1 indicates arthritis. Suppression of 
proteoglycan synthesis is measured by uptake of 35S-sulfate by patellae. 
Arthritic patellae are compared to patellae from contralateral nonarthritic 
knee joints. Data are mean ± SD of 2 experiments. In cach experiment 
at least 6 mice were used,
Maximal suppression (55%) was seen at 48 h and declined 
thereafter. At Day 4, there was no more evidence of sup­
pression, whereas at Day 7 and Day 10, surplus production 
of proteoglycan of respectively 68 and 44% was found.
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In vivo effect of blocking IL-1 on proteoglycan synthesis. IL-1 
production was neutralized in 2 ways. Firstly by iv injec­
tion of polyclonal antibodies directed against the a and B form 
iv shortly before arthritis induction; secondly, by giving IL-1 
receptor antagonist (IL-lra) systemically by implanting os­
motic pumps ip.
Neutralizing the a form of IL-1 resulted in a significant 
decrease of swelling (46%). The potency of anti-IL-1 fí was 
comparable and neutralization resulted in a 44% decrease 
in swelling. A combination of anti-IL-1 a and R was most 
effective and reduced swelling by 90% (Table 1). Total knee 
joint sections showed that influx of cells was significantly 
lowered. The a and B form were equipotent in this respect. 
Both antibodies given together resulted in significantly 
reduced cell influx.
To confirm findings with neutralizing antibodies, IL-1 bio­
activity was blocked with IL-lra. Osmotic pumps were im­
planted in the peritoneal cavity and set to release constant 
amounts of IL-lra for 7 days (1.2 mg IL-lra/day). In the 
control group empty pumps were implanted. Two days af­
ter arthritis induction, swelling in the IL-lra treated group 
was significantly decreased (83% inhibition). Influx of cells 
was also significantly decreased (Figure 3). Only in the syn­
ovial layer small numbers of inflammatory cells were present. 
Suppression of proteoglycan synthesis was fully blocked by 
the IL-lra as measured in the patella assay (Table 2). In both 
anti-IL-1 and IL-lra treated groups synthesis of proteogly­
can in the contralateral nonarthritic knee joint was higher 
— although values did not reach statistical significance — 
compared to the contralateral joints of control mice. IL-lra 
given to normal mice had no effect on proteoglycan synthe­
sis (data not shown).
In additional studies, mice treated with anti-IL-1 antibod­
ies, IL-lra, or control phosphate buffered saline (PBS) were 
given 35S-sulfate ip at Day 2 after ICA induction. Three 
hours thereafter total knee joints were processed for 
autoradiography and proteoglycan synthesis studied. Figure 
3C shows that patellar and femoral cartilage surfaces in con­
trol, arthritic knee joints show fewer black spots around the 
chondrocytes, indicating low proteoglycan synthesis (Figure 
3C). Both anti-IL-1 antibodies and IL-lra treated groups
Table 2. Inflammation and inhibition of proteoglycan 
synthesis in ICA. Effect of neutralization of IL-1 by IL-1 ra
ICA IL-1 ra
" mTc uptake L/R 1.72 ± 0.04 1.12 i  0.03
Proteoglycan L 667 + 43 1804 ± 28
synthesis (cpm) R 1241 ± 43 1455 ± 99
Inhibition (%) 50 -16*
IL-1 was neutralized by giving IL-1 ra before arthritis induction. IL-1 ra 
containing osmotic pumps were implanted in the peritoneal cavity. A constant 
release of 1.2 mg IL-1 ra/day was set. Joint swelling was measured by 
" mTc uptake. Values represent the mean ± SD of 3 experiments. In each 
experiment at least 6 mice were used/group. Data were statistically evaluated 
by Mann-Whitney U test. * p < 0,05.
(Figure 3D) showed normal synthesis, comparable to non­
arthritic joints injected with PBS.
In vivo effect of blocking TNF on proteoglycan synthesis. 
Although no free biologically active TNF-a could be detected 
in early immune complex arthritis, this cytokine might func­
tion locally. To investigate the in vivo role of local TNF-o: 
production in suppression of proteoglycan synthesis, an ex­
cess of neutralizing anti-TNF-a Mab (50,000 U) was given 
iv before arthritis induction. Swelling measured by "™Tc 
uptake was not changed (Table 3). Total knee joint sections 
stained by hematoxylin/eosin also showed that influx of cells 
in the synovium and joint cavity was not changed. Measur­
ing proteoglycan synthesis revealed that neutralization of 
TNF-a could not block suppression (Table 3). Similar sup­
pression was found in control (rat IgG treated) and anti-TNF 
treated groups.
Table 3. Inflammation and inhibition of proteoglycan 
synthesis in ICA. Effect of anti-TNF
Joint ICA Anti-TNF
" mTc uptake L/R 1.57 ± 0.04 1.51 ± 0.03
Proteoglycan L 667 ± 43 804 i  28
synthesis (cpm) R 1241 ± 43 1455 ± 99
Inhibition (%) 46 45
TNF was neutralized by giving anti-TNF antibodies (Vlq) before arthritis 
induction. Values represent the mean ± SD of 2 experiments, In each 
experiment at least 6 mice/group were tested. Values were statistically 
evaluated by Mann-Whitney U test.
Table 1. Inflammation and inhibition of proteoglycan synthesis in ICA. Effect of 
neutralization of a and j9 IL-1 with anti-IL-1 antibodies
ICA Anti-IL-1 a Anti-IL-lß Anti-IL-1 a + ß
" mTc uptake L:R 1.72 ± 0.02 1.39 ± 0.16 1.40 ± 0.02 1.07 ± 0.03
Proteoglycan L 915 ± 259 1431 ± 238 1432 ± 264 2699 ± 385
synthesis (cpm) R 1735 ± 236 2012 ± 64 1979 ± 358 2085 ± 120
Inhibition (%) 47 29* 28* -29*
Swelling was measured using the " mTc uptake method. L:R — ratios indicating amount of swelling; > 1.1 
indicates significant swelling. Proteoglycan synthesis was measured by uptake of 35S by patellae from the arthritic 
(L) knee joint compared to the contralateral nonarthritic (R) knee joint. Values represent the mean ± SD of
3 experiments. In each experiment at least 6 mice/group were tested. Data were statistically evaluated by Mann- 
Whitney U test. * p < 0,05.
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Cell influx and inhibition of proteoglycan synthesis. We in­
vestigated whether influx of cells in arthritic knee joints im­
pairs proteoglycan synthesis. To investigate this, mice were 
made neutropenic either by total body irradiation or cyclo­
phosphamide treatment. Both methods induced more than 
98% depletion of peripheral PMN. IL-1 levels in arthritic 
neutropenic j oints, measured at 6 hs were significantly higher 
compared to control arthritic knee joints. Maximal levels 
were found at 6 h and remained high at 24 h (Figure 4). 
Production of IL-1 at 6 h varied between 70-120 pg and at 
24 h between 10-30 pg/specimen. At 48 h only minimal 
amounts of IL-1 were detected in both groups. Again no bio­
logically active TNF-a was detected in neutropenic arthrit­
ic joints. No IL-1 nor TNF-a was detected in washouts of 
contralateral nonarthritic neutropenic joints.
Total knee joint sections showed that only minimal amounts 
of PMN were observed in arthritic knee joints. Influx of 
monocytes was also minimal. Total body irradiation had no 
significant (18% inhibition) side effects on proteoglycan syn­
thesis as measured in the contralateral nonarthritic knee joint 
(Table 4). Cyclophosphamide treatment raised proteoglycan 
synthesis by 33 %. Arthritis induction in control and neutro­
penic arthritic knee joints showed comparable suppression 
of proteoglycan synthesis (Table 4). This suggests that local 
production of mediators by resident cells is sufficient for pro­
teoglycan suppression.
Table 4. Inhibition of proteoglycan synthesis in neutropenic 
arthritis mice
35S-PG Synthesis
Animals Left Right %
Control 1236 ± 290 540 ± 161 56
neutropenica 847 ± 175 452 ± 120 47
Control 814 ± 262 688 ± 143 31
neutropenicb 1188 ± 182 917 ± 224 25
Mice were made neutropenic by either total body irradiation (750 rad)1' or 
cyclophosphamide treatment. Patellae were dissected 2 days after induction 
of ICA. Proteoglycan synthesis was measured by uptake of 35S by patellae 
derived from the arthritic (L) knee joint and compared to contralateral 
nonarthritic (R) knee joint. Data represent the mean ± SD of 2 experiments. 
In each experiment at least 6 mice were tested. Data were statistically 
evaluated by Mann-Whitney U test.
Direct role of IL-1 in proteoglycan degradation. We studied 
the degradation of cartilage proteoglycan by prelabeling of 
the cartilage proteoglycans with 35S-sulfate and analyzing 
the loss of 35S-proteoglycan after arthritis induction. In ir­
radiated and cyclophosphamide treated mice less 35S uptake 
by the patellae was observed before induction of ICA, com­
pared to the control group. Proteoglycan loss among groups 
was compared. Loss of proteoglycan from patella in arthrit­
ic joints was compared to that from patella in contralateral 
nonarthritic joints. At Day 2 , a 60% loss of proteoglycan 
was found in normal mice with ICA. Despite high IL-1 levels
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Fig, 4. IL-1 production by patellae 6,24 and 48 h after induction of ICA in knee joints of control (A) and neutropenic 
(B) mice. Mice were made neutropenic by either total body irradiation (750 rad) or cyclophosphamide treatment. 
Washout dilutions of 10, 20, 40 and 80-fold were tested. The most sensitive dilution to calculate IL-1 levels 
was 80 (variation between experiments was 38%). Neutropenic arthritic knee joint produced significantly higher 
IL-1 levels compared to control arthritic knee joints. At 6 h 70-120 pg was detected versus 10-30 pg/specimen 
at 24 h. No IL-1 was detected in washouts of PBS injected contralateral nonarthritic patellae. In each experiment 
at least 5 mice were tested; 5 experiments were done. The above shows a representative experiment. Dilutions 
were tested twice in the bioassay and are expressed as mean ± SD.
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Table 5. Proteoglycan degradation in neutropenic arthritic 
mice
Treatment Control (%) Neutropenic (%)
Total body irradiation (750 rad) 56 ±1 10 ± 6*
Cyclophosphamide 60 i  7 11 ± 14*
Effect of PMN depletion on proteoglycan degradation. Mice were made 
neutropenic either by total body irradiation (750 rad) or cyclophosphamide 
(Day -4, 100 mg/kg; Day — 1, 80 mg/kg) treatment. Patellae, prelabeled 
with 35S (50 /¿Ci/mouse) in vivo before arthritis induction, were dissected 
48 h after ICA induction. The 35S content of the arthritic patella is 
expressed as % of 35S content of the contralateral noninflamed patellae. 
Values represent the mean ± SD of 2 experiments, each consisting of at 
least 7 animals. Data were statistically evaluated by Mann-Whitney U test. 
* p < 0.05.
in neutropenic mice (Figure 1), we observed only minor pro­
teoglycan degradation in neutropenic mice with ICA (Table 
5). This suggests that the direct effect of IL-1 on proteogly­
can breakdown is marginal and the main effect of IL-1 is 
through indirect regulation of cell influx and amplification 
of activation of synovial cells.
DISCUSSION
Our results suggest that IL-1 but not TNF-a is the main 
cytokine involved in cartilage damage during experimental 
ICA. IL-1 directly mediates suppression of proteoglycan syn­
thesis. Its direct effect on loss of proteoglycan seems only 
limited but as the most important regulator of cell influx IL-1 
mediates cartilage degradation indirectly.
Neutralization of IL-1 in ICA leads to full blockade of in­
hibition of proteoglycan synthesis but also to significantly 
lowered influx of inflammatory cells. The same observations 
were made in the collagen type II induced arthritis15*25*26. 
This did not exclude the possibility that decreased cell in­
flux might well be responsible for observed blockade of in­
hibition of proteoglycan synthesis. In our study we found, 
however, that suppression of proteoglycan synthesis was 
similar in both neutropenic and control arthritic knee joints, 
indicating that inflammatory cells are not involved in sup­
pression of proteoglycan synthesis. This confirms recent 
observations in other arthritis models such as methylated 
bovine serum albumin induced arthritis7 and zymosan in­
duced arthritis14. All models studied to date indicate IL-1 is 
directly responsible for inhibition of proteoglycan synthesis.
The potency of IL-1 as an inhibitor of proteoglycan syn­
thesis was already suggested by single mediator studies, IL-1 
is a potent inhibitor of proteoglycan synthesis. Injection of 
recombinant IL-1 in murine knee joints induced a severe in­
hibition of proteoglycan synthesis3. IL-1 is released in sig­
nificant amounts shortly after ICA induction. Neutralization 
of both forms of IL-1 by anti-IL-1 antibodies or blockade 
of its biological effect by IL-lra fully prevented inhibition 
of proteoglycan synthesis. This is in agreement with earlier 
studies in which full blockade of proteoglycan inhibition was
found after IL-1 neutralization with a combination of a and 
B antibodies or IL-lra in antigen induced arthritis14 and col­
lagen type II arthritis (manuscript in preparation). In the ICA 
both IL-1 a and are produced although the a form is more 
prominent8. Using anti-IL-1 a and anti-IL-lfl antibodies 
separately showed that each form mediates part of the sup­
pression of proteoglycan synthesis. Both IL-1 forms have 
been described to bind IL-1 type I receptor present on chon­
drocytes. The IL-1 type I receptor probably mediates the in­
hibiting effect27.
In contrast to anti-IL-1 antibodies, high amounts of IL-lra 
are needed for optimal neutralization of the IL-1 effects. To 
block IL-1 effects on murine cartilage a 1000-fold excess 
of IL-lra was necessary. Like IL-1, 17 kDa IL-lra has a 
high clearance rate of 30 min. We found that the effects of 
an intraarticular injection of 1 ng could be blocked by the 
IL-lra levels released by the osmotic pumps14. Since the 
amount of IL-1 formed during ICA is much less than 1 ng, 
these IL-lra blood levels were sufficient for neutralization. 
A similar level is not easily achieved with repeated injec­
tions. Because of the high removal rate of IL-lra, multiple 
injections are necessary to reach sustained, high concentra­
tions. Multiple injections may, however, alter the course of 
arthritis by stress induction. Of interest, proteoglycan syn­
thesis of contralateral nonarthritic joints was higher in IL-lra 
treated mice compared to control mice. This suggests that 
IL-lra may elevate normal proteoglycan synthesis. However, 
IL-lra treatment of normal animals, in which no arthritis was 
induced, had no effect on proteoglycan synthesis. This indi­
cates that systemic effects are induced by a surplus of IL-1, 
generated in the arthritic knee joint and that this is effec­
tively blocked by IL-lra.
In contrast to IL-1, TNF-a could not be detected in early 
arthritis. No detectable biologically active TNF-a levels 
could be found in control or neutropenic arthritic knee joints. 
This indicates that TNF-a production is below 0.3 pg/patel- 
la. High amounts of neutralizing anti-TNF-a antibodies given 
before arthritis had no effect oil feither cell influx or suppres­
sion of proteoglycan synthesis. Other species of anti-TNF- 
a Mab showed similar results (data not shown). In vitro 
studies have shown that TNF-a may cause significant pro­
teoglycan suppression. TNF-a was however less potent than 
IL-1, and large amounts of TNF-a (100 ng/ml) were neces­
sary to induce suppression10. In our model, TNF-a produc­
tion is too low to induce suppression. In other arthritis models 
like collagen type II both TNF-a and IL-1 seem to be im­
portant in cell influx15'28-29. IL-1 appeared, however, to be 
the dominant cytokine25, and blockade of IL-1 increased in­
flux of cells and normalized suppression of proteoglycan syn­
thesis, whereas blockade of TNF-a had only moderate ef­
fects. In bacterial induced joint inflammation, TNF-a seems 
to be the more dominant cytokine involved in cell influx6-30. 
Furthermore cytokine production by immune complexes and 
its effect on tissue damage might be tissue dependent, Im-
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mune complex (IC) mediated inflammation in the skin activate synovial fibroblasts. Leakage of synovial vessels ele-
seemed predominantly regulated by IL-1 whereas in the lung vates the presence of fibrinolytic enzymes like plasmin,
both TNF and IL-1 were important31. which may transform latent cartilage degrading enzymes in
Apart from local IL-1 production by resident cells, infiltrat- its active form. Whether monocytes and/or synovial cells in
ing inflammatory cells may also significantly contribute to this model are responsible for external cartilage degradation
the cytokine load since these cells contain small amounts of is currently under investigation.
IL-1 and TNF. Local activation of these infiltrated cells, e.g., Our results indicate that in ICA, IL-1 is the major cytokine
reconstruction of damaged cartilage.
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with cationic IC32 may release these cytokines. In our study involved in suppression of proteoglycan synthesis. Inflam- 
we found however that in the absence of PMN even higher matory cells seem not to be involved in suppression of pro- 
IL-1 levels were expressed for longer periods. This indicates teoglycan synthesis. These cells are however involved in pro- 
that the PMN, which is the predominant cell during early teoglycan loss16. Since IL-1 is the main cytokine involved 
arthritis, affects biologically active IL-1 levels by clearing in cell influx, this cytokine also indirectly regulates proteogly- 
the triggering IC responsible for IL-1 production16, Further- can loss. Neutralizing the surplus of IL-1 generated in ar- 
more, apart from releasing proinflammatory cytokines, the thritic joints may be an important approach to stimulate 
PMN also produce cytokine inhibitors such as IL-lra33 or 
enhance expression and shedding of IL-1 receptor type II.
IL-1 receptor type II may act as a decoy to catch IL-1, thus 
preventing biological activity34. IL-1B has a higher affinity 
for type II than the a form27 and binds in larger amounts 
in the presence of PMN. This may also explain why 80% 
of the IL-1 signal we detected in the bioassay contained the 
a form.
So although PMN downregulate IL-1 the remaining IL-1 
is still sufficient for maximum suppression of proteoglycan 
synthesis. Apart from reducing synthesis, IL-1 can resorb 
cartilage in 2 ways: first, within the cartilage, by activating 
chondrocytes that resorb cartilage from the inside and second 
from outside by directing the influx of infiltrating cells. The 
latter may release enzymes into the synovial fluid, which may 
degrade cartilage starting at the cartilage surface. Our study 
indicates that in arthritic joints in the absence of inflamma­
tory cells, IL-1 levels were even higher. Nevertheless IL-1 
levels seem insufficient to induce the loss of proteoglycan 
observed in control arthritic knee joints. Earlier studies rev­
ealed that higher doses of IL-1 are needed for cartilage 
resorption than for suppression of proteoglycan synthesis11.
This indicates that IL-1 levels secreted during arthritis may 
be too low to cause cartilage resorption directly, and influx 
of cells is necessary to induce degradation. The influx of cells 
during ICA is for the greater part dependent on IL-18.
Blockade of IL-1 by anti-IL-1 antibodies or IL-lra stops the 
influx of PMN. Although there is little effect on the influx 
of monocytes, cartilage degradation remained at 50%8 or 
even 75% in IL-lra treated arthritic animals (manuscript in 
preparation). This suggests that the interaction between in­
filtrating monocytes and synovial cells may be the most im­
portant mechanism in cartilage degradation during ICA. On 
one hand, synovial macrophages and fibroblasts activated by 
IC release cartilage degrading enzymes like 
metalloproteinases35. On the other hand infiltrating mono­
cytes have the capacity to release proteoglycan degrading 
enzymes. Cationic IC, which strongly attach to synovial tis­
sues due to their charge8, may activate infiltrating mono­
cytes to release these enzymes as well as other factors that
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